Categories: News

Rigrodsky & Long, P.A. Reminds Investors of Investigation of New Providence Acquisition Corp. Merger

WILMINGTON, Del., Jan. 08, 2021 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating New Providence Acquisition Corp. (“New Providence”) (NASDAQ GS: NPA) regarding possible breaches of fiduciary duties and other violations of law related to New Providence’s agreement to merge with AST & Science LLC.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-new-providence-acquisition-corp.

You may contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com.

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
https://rl-legal.com

Staff

Recent Posts

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder

Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related DepressionMUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) --…

13 minutes ago

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply…

13 minutes ago

The Ultimate Credentialing Solution for Independent Practitioners: Transform Your Practice in 2025 With CredyApp Solo

"Solo practitioners face unique challenges in managing their credentialing needs," says Olga Khabinskay, Director of…

13 minutes ago

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

In Q1 2025, the Company will discuss the plans for NDA submission under a potential…

14 minutes ago

ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical…

14 minutes ago